Strides Acrolab secures WHO pre-qualification for anti-malarial drugs
The company plans to launch the product immediately.
New Delhi, June 25, 2013: The drug firm Strides Acrolab today announced that it has received World Health Organisation (WHO) pre-qualification for its anti-malarial tablets and it plans to launch the product immediately. It may be noted here that the anti-malarial Artemether and Lumifantrine (AL) tablets constitutes over 80 per cent of artemesinin combination therapy (ACT) procured under Global Fund and other similar programmes.
WHO prequalification of medicines is a service provided by WHO to assess the quality, safety and efficacy of medicinal products. The Artemether and Lumefantrine tablets were added to the WHO's Essential Medicines list in the year 2002.
The company plans to manufacture this product at its USFDA approved and WHO pre-qualified facility in Bengaluru.